A meta-analysis of 230 studies shows robotic surgery improves outcomes compared to laparoscopic and open approaches in oncology.
Quiver AI Summary
A recent meta-analysis published in the Annals of Surgery evaluated the 30-day surgical outcomes of robotic, laparoscopic, and open surgical approaches across seven oncological procedures, leveraging data from 230 studies conducted over the past 12 years in 22 countries. The research, spearheaded by scientists from Intuitive and Massachusetts General Hospital, highlighted the advantages of using Intuitive's da Vinci robotic system, noting fewer conversions to open surgery, reduced blood loss, lower rates of blood transfusions, fewer postoperative complications, and shorter hospital stays compared to traditional methods. Although da Vinci surgeries required slightly more operative time, the overall benefits underscore the increasing value of robotic surgery for improving patient outcomes in complex surgical scenarios. Intuitive, a leader in minimally invasive care, emphasizes its commitment to enhancing surgical precision and patient recovery through advanced robotic technologies.
Potential Positives
- Publication of a peer-reviewed meta-analysis in the Annals of Surgery highlights the advantages of robotic surgery using Intuitive's da Vinci system over traditional methods.
- The study demonstrated significant clinical benefits, including reduced conversion rates to open surgery, lower blood loss, and fewer readmissions, which may enhance the appeal of the da Vinci system among healthcare providers.
- New data positions Intuitive as a leader in the evolving field of robotic surgery, providing compelling evidence for decision-makers considering robotic solutions in surgical practices.
- This research reinforces the value of the da Vinci system in improving surgical outcomes and supports Intuitive's vision of advancing minimally invasive care, potentially leading to increased adoption and market share.
Potential Negatives
- The study did not review oncologic outcomes, which may limit the comprehensiveness and applicability of the findings in assessing the overall effectiveness of robotic surgery.
- The noted operative time for da Vinci cases being significantly longer than both laparoscopic and open surgeries could raise concerns regarding efficiency and resource utilization in surgical settings.
- Despite the benefits highlighted, the mention of potential serious complications associated with da Vinci surgery, including injury to tissues and organs, could deter hospitals and patients from adopting the technology.
FAQ
What does the recent meta-analysis in the Annals of Surgery focus on?
The meta-analysis evaluates 30-day surgical outcomes for robotic, laparoscopic, and open surgery across seven oncological procedures.
How many studies were analyzed in the research?
The analysis included 230 studies, comprising randomized trials, prospective studies, and database reviews from 22 countries.
What are the benefits of robotic surgery with the da Vinci system?
Robotic surgery showed fewer conversions, less blood loss, fewer transfusions, and shorter hospital stays compared to laparoscopic and open surgery.
How does robotic surgery compare in terms of complications?
Da Vinci robotic cases were 10% less likely to experience 30-day postoperative complications compared to laparoscopy, and 44% less compared to open surgery.
What technologies enhance the da Vinci Surgical System?
The system features advanced 3DHD vision, wristed instrumentation, and improved precision for surgeries in tight anatomical areas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Congressional Stock Trading
Members of Congress have traded $ISRG stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 2 purchases worth up to $30,000 on 07/22, 06/25 and 0 sales.
- REPRESENTATIVE GREG LANDSMAN has traded it 3 times. They made 1 purchase worth up to $50,000 on 06/20 and 2 sales worth up to $65,000 on 07/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 76 times in the past 6 months. Of those trades, 0 have been purchases and 76 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- ROBERT DESANTIS (EVP & Chief Strategy & Corp Op) has traded it 34 times. They made 0 purchases and 34 sales, selling 6,073 shares.
- JAMIE SAMATH (CFO and Head of Business Techn) has traded it 6 times. They made 0 purchases and 6 sales, selling 23,468 shares.
- MYRIAM CURET (EVP & Chief Medical Officer) has traded it 5 times. They made 0 purchases and 5 sales, selling 16,284 shares.
- GARY S GUTHART (CEO) has traded it 6 times. They made 0 purchases and 6 sales, selling 56,419 shares.
- MARK BROSIUS (SVP & Chief Mfg and Supply Cha) has traded it 6 times. They made 0 purchases and 6 sales, selling 2,216 shares.
- BRIAN EDWARD MILLER (EVP & Chief Digital Officer) sold 2,553 shares.
- AMY L LADD sold 450 shares.
- GARY LOEB (General Counsel) sold 300 shares.
- HENRY L CHARLTON (SVP & Chief Commercial and Mkt) has traded it 13 times. They made 0 purchases and 13 sales, selling 40,243 shares.
- AMAL M JOHNSON sold 2,943 shares.
- CRAIG H BARRATT has traded it 2 times. They made 0 purchases and 2 sales, selling 2,800 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Hedge Fund Activity
We have seen 960 institutional investors add shares of $ISRG stock to their portfolio, and 749 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 2,413,491 shares (-35.5%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 1,316,215 shares (-86.8%) from their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,246,054 shares (-7.9%) from their portfolio in Q3 2024
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 1,137,475 shares (+inf%) to their portfolio in Q3 2024
- INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC added 1,088,415 shares (+49383.6%) to their portfolio in Q3 2024
- JPMORGAN CHASE & CO added 1,076,519 shares (+12.1%) to their portfolio in Q3 2024
- EDGEWOOD MANAGEMENT LLC removed 939,202 shares (-23.6%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Analysis included 230 studies—a mix of randomized, prospective, and database research
SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:ISRG)
The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures , comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective studies, and 122 database reviews. Each surgical approach represented more than a million procedures.
The meta-analysis, conducted by scientists from Intuitive and Massachusetts General Hospital, demonstrated multiple benefits for robotic surgery using Intuitive’s da Vinci system as compared to laparoscopy and open surgery.
“Robotic surgery with da Vinci showed fewer conversions, less blood loss, fewer blood transfusions, fewer readmissions and reoperations, and a shorter length of stay after 30 days,” said Intuitive Executive Vice President and Chief Medical Officer Myriam Curet, MD.
“The editors at the Annals of Surgery thoroughly scrutinized and peer-reviewed this study prior to acceptance,” said Curet. “The quality of scientific data we are seeing after decades of robotic surgery underscores the value that the da Vinci robotic approach continues to have for improved surgical care.”
Notable study results included:
- Da Vinci robotic cases were 56 percent less likely to convert to open surgery versus laparoscopy.
- Da Vinci robotic cases saw less blood loss versus open, comparable blood loss with laparoscopy.
- Da Vinci robotic cases were 21 percent less likely to require blood transfusions versus laparoscopy and 75 percent versus open.
- Da Vinci cases were 10 percent less likely to experience 30-day postop complications versus laparoscopy; 44 percent versus open.
- Da Vinci cases saw a half-day savings in hospital stay compared to laparoscopy and 1.9 days compared to open.
- Operative time for da Vinci cases was 17.7 minutes longer than laparoscopy and 40.9 minutes longer than open.
“The data presented in our study describes the value of robotics in both the controlled clinical setting of randomized controlled trials and in the ‘real-clinical-world’ of population-based studies,” said Rocco Ricciardi, MD, MPH, lead study author and chief of colon and rectal surgery at the Massachusetts General Hospital.
“Ultimately, demonstrating population-based gains with robotics allows us to determine value of robotic procedures for the average person who might need surgery.”
Traditional minimally invasive surgery offers many benefits but presents several technical limitations—notably lower quality vision and depth perception, camera instability, limited range of motion and dexterity due to the straight and rigid hand-held instruments, and it can take a severe physical toll on the surgeon.
Intuitive technology introduced in the da Vinci surgical system has helped surgeons overcome many of those technological limitations via advanced 3DHD vision, wristed instrumentation, and greater precision, especially in deep, limited, or narrow areas of the body such as the chest, abdomen, and pelvis.
There have been numerous studies comparing perioperative outcomes between robotic, laparoscopic, and open surgery but they have focused on individual procedures, which result in procedure-specific evaluations.
Intuitive’s study in the Annals of Surgery looked at randomized controlled trials, prospective cohort, and database studies published within the last 12 years, and it shows multiple benefits for robotic surgery using the da Vinci system compared to laparoscopic and open surgery, which may be useful to decision makers who are considering the use of robotics in a multi-specialty setting.
The study scope focused on 30-day outcomes specific to oncology procedures that often require deep and narrow surgical access. It did not review oncologic outcomes.
About Intuitive
Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About da Vinci Surgical Systems
There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
For more information, please visit the company’s website at www.intuitive.com .
Important Safety Information
Serious complications may occur in any surgery, including da Vinci surgery, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs and conversion to other surgical techniques which could result in a longer operative time and/or increased complications. For summary of the risks associated with surgery refer to www.intuitive.com/safety.
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, refer to the associated user manual(s) or visit https://manuals.intuitivesurgical.com/market.
Individual outcomes may depend on a number of factors—including but not limited to—patient characteristics, disease characteristics, and/or surgeon experience.
Contact Information
Peper Long, Intuitive
202-997-7373
[email protected]